drugset / Trial / NCT06843681
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
Phase 2
Enrolling by invitation
54 enrolled
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Peking University Shenzhen Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II single-center single-arm clinical study designed to analyze the efficacy and safety of trastuzumab combined with taxane neoadjuvant therapy for HER2-positive breast carcinoma in situ (or with invasive carcinoma).
Timeline
- Start
- 2025-03-01
- Primary completion
- 2027-01-01
- Completion
- 2030-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |